The distribution of 5-HT1D and 5-HT1E binding sites in human brain.
Total 5-HT1, 5-HT1D and 5-HT1E binding sites were measured in homogenates of human frontal cortex, hippocampus, amygdala, globus pallidus, caudate and putamen. Combined 5-HT1D/1E sites were the predominant 5-HT1 subtype (66-95% of total 5-HT1 sites in all regions except hippocampus (38% of total 5-HT1 sites). Globus pallidus contained the highest density and the highest proportion of 5HT1D sites (74% of total 5-HT1 sites). 5HT1D sites in the other brain areas accounted for 19-27% of the total 5-HT1 sites. The highest densities and the highest proportions of 5-HT1E sites were in caudate (72%) and putamen (64%) and the lowest density and lowest proportion in hippocampus (16%).
Lowther
S
S
Department of Pharmacology and Clinical Pharmacology, St. George's Hospital Medical School, London, UK.
De Paermentier
F
F
Crompton
M R
MR
Horton
R W
RW
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology; D001921:Brain / Q000033:anatomy & histology*; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology*; D004873:Ergolines / Q000494:pharmacology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D010869:Pindolol / Q000494:pharmacology; D011985:Receptors, Serotonin / Q000378:metabolism*
D000978:Antiparkinson Agents; D004873:Ergolines; D011985:Receptors, Serotonin; D010869:Pindolol; C031649:mesulergine